Sensei Biotherapeutics Future Growth
Future criteria checks 0/6
Sensei Biotherapeutics's earnings are forecast to decline at 10.3% per annum. EPS is expected to grow by 9.7% per annum.
Key information
-10.3%
Earnings growth rate
9.7%
EPS growth rate
| Biotechs earnings growth | 21.3% |
| Revenue growth rate | n/a |
| Future return on equity | -62.6% |
| Analyst coverage | Low |
| Last updated | 29 Feb 2024 |
Recent future growth updates
Recent updates
Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?
Nov 03
We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully
Jul 02Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Mar 14We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely
Aug 14Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06
Aug 09Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation
Apr 18Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans
Nov 16Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -45 | N/A | -54 | 2 |
| 12/31/2025 | N/A | -39 | N/A | -43 | 2 |
| 12/31/2024 | N/A | -30 | N/A | -32 | 3 |
| 12/31/2023 | N/A | -34 | -32 | -32 | N/A |
| 9/30/2023 | N/A | -39 | -36 | -35 | N/A |
| 6/30/2023 | N/A | -45 | -38 | -38 | N/A |
| 3/31/2023 | N/A | -46 | -40 | -40 | N/A |
| 12/31/2022 | N/A | -49 | -39 | -39 | N/A |
| 9/30/2022 | N/A | -46 | -38 | -37 | N/A |
| 6/30/2022 | N/A | -42 | -37 | -36 | N/A |
| 3/31/2022 | N/A | -41 | -32 | -30 | N/A |
| 12/31/2021 | N/A | -37 | -32 | -30 | N/A |
| 9/30/2021 | N/A | -33 | -27 | -25 | N/A |
| 6/30/2021 | N/A | -28 | -28 | -25 | N/A |
| 3/31/2021 | N/A | -23 | -24 | -22 | N/A |
| 12/31/2020 | N/A | -20 | -19 | -18 | N/A |
| 9/30/2020 | N/A | -23 | -18 | -17 | N/A |
| 12/31/2019 | N/A | -21 | -9 | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SNSE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SNSE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SNSE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if SNSE's revenue is forecast to grow faster than the US market.
High Growth Revenue: SNSE is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SNSE is forecast to be unprofitable in 3 years.